Clinical Trial Finder

General Inclusion Criteria.

• - Male or female age ≥18 yrs.

• - Carcinoid Heart Disease.

• - NYHA Class II - IV.

• - Severe symptomatic tricuspid regurgitation.

• - Inoperable due to active tumour process or patient declines an operative intervention.

• - Patient willing and able to consent and comply with specified study evaluations.

• - Adequate understanding of written or spoken English (to complete validated questionnaires) General Exclusion Criteria.

• - Previous tricuspid valve repair or replacement.

• - Permanent vena cava filter.

• - Mega atrium.

• - Tricuspid valve stenosis.

• - Thrombosis of lower venous system.

• - Severe uncontrolled hypertension (Systolic BP ≥ 180 mmHg and/or Diastolic BP ≥ 110 mm Hg) - Active endocarditis.

• - Subject is on chronic dialysis.

• - Bleeding disorders or hypercoaguable state.

• - Hemodynamic instability or on IV inotropes.

• - Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically eg contrast.

• - Contraindication to anticoagulants or antiplatelet medication.

• - Known allergy to Nitinol (Titanium or Nickel) alloy, gold or porcine tissue.

• - Untreated clinically significant coronary artery disease requiring revascularization.

• - Any Percutaneous Coronary Intervention (PCI) or transcatheter valvular intervention within 30 days prior to the index procedure or planned 3 months post the index procedure.

• - Myocardial Infarction (MI) or known unstable angina within the 30 days prior to the index procedure.

• - Pregnant or lactating; or female of childbearing potential with a positive pregnancy test 24 hours before any study-related radiation exposure.

• - Contraindication to long-term anticoagulation.

• - Life expectancy according to tumour development is less than 12 months.

- Impaired judgment and/or is undergoing emergency treatment

After being informed about the study and the potential risks and benefits, participants who provide written consent will be screened to make sure they fulfil the study entry requirements. This will involve a detailed medical history, a CT and an echo scan. Once it is agreed that the participant is suitable for the study, a custom-made TRICENTO valve is prescribed and made. Participants need to be admitted to hospital for the TRICENTO device to be implanted. Before the device is implanted the participant will have further tests and measurements completed eg ECG, a Cardiac MRI, physical measurements such as height, weight and blood pressure, blood tests, questionnaires and measuring how far they can walk in 6 minutes. The device is implanted in a cath lab procedure which should take about 30-60 minutes in total. Participants should be discharged from hospital about 2-3 days later after recovery and further echocardiogram, blood tests and questionnaires. Follow up visits are at 1 month and 6 months after the procedure. The following measurements such as an ECG, echocardiogram, and physical measurements (height, weight and blood pressure), some blood tests, questionnaires and measuring how far they can walk in 6 minutes will be repeated at 1 month and at 6 months after the procedure. A cardiac MRI will also be repeated at 6 months after the procedure. All these tests are to measure whether the TRICENTO valve improves the participant's heart function, symptoms and quality of life.

Arms

Experimental: Transcatheter Tricuspid Valved Stent Graft intervention

Participants who have carcinoid heart disease with severe symptomatic tricuspid regurgitation and with a significant backflow in the caval and hepatic veins will be treated with the implantation of the Transcatheter Tricuspid Valved Stent Graft

Interventions

Device: - Transcatheter Tricuspid Valved Stent Graft

All participants meeting the inclusion and none of the exclusion criteria will be enrolled. A custom-made Transcatheter Tricuspid Valved Stent Graft based on CT to define anatomic dimensions will be made. The system consists of a custom-made valved stent graft delivery system, a custom-made valved stent graft bioprosthesis and a loading system. The bioprosthesis is self-expanding and consists of a stent graft spanning from the inferior vena cava to the superior vena cava and a lateral bicuspid valve element made of thin porcine pericardial leaflets requiring a low closing pressure, and Nitinol support structures. The participants will undergo a minimally invasive, catheter-based procedure to implant the bioprosthesis which is delivered through a 24 French delivery system via transfemoral access. The device can be repositioned and is retrievable.